OFFICE OF THE SECRETARY OF STATE
LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON

ARCHIVES DIVISION
STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

FILED
06/18/2024 8:49 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

BP 55-2024
CHAPTER 855
BOARD OF PHARMACY

FILING CAPTION: Amends rule to limit labeling exemption to nasal sprays consistent with 2023 SB 450

EFFECTIVE DATE: 06/20/2024

AGENCY APPROVED DATE: 06/13/2024

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland,OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

AMEND: 855-115-0350

RULE TITLE: Services: Prescribing Practices - Short-acting Opioid Antagonists

NOTICE FILED DATE: 04/17/2024

RULE SUMMARY: Amends existing rule by adding that the labeling exemption only applies to nasal sprays as stated in 2023 SB 450.

RULE TEXT:

(1) A Pharmacist may prescribe any FDA approved short-acting opioid antagonist (e.g., naloxone, nalmefene) and the necessary medical supplies to administer a short-acting opioid antagonist for opiate overdose:
(a) When dispensing any opiate or opioid prescription in excess of 50 morphine milligram equivalents (MME);
(b) To an individual seeking a short-acting opioid antagonist;
(c) To an entity seeking a short-acting opioid antagonist.
(2) A Pharmacist is not required to label the prescription according to OAR 855-041-1130 if dispensing a FDA approved short-acting opioid antagonist in the form of a nasal spray.
(3) The Pharmacist must document the encounter, the prescription and maintain records according to OAR 855-104-0055.

STATUTORY/OTHER AUTHORITY: ORS 689.205

STATUTES/OTHER IMPLEMENTED: ORS 689.305, ORS 689.681, ORS 689.682, ORS 689.684